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Abstract
In epithelial tumors, the platelet-derived growth factor receptor B (PDGFRB) is mainly expressed by stromal cells of
mesenchymal origin. Tumor cells may also acquire PDGFRB expression following epithelial-to-mesenchymal transi-
tion (EMT), which occurs during metastasis formation. Little is known about PDGFRB signaling in colorectal tumor
cells. We studied the relationship between PDGFRB expression, EMT, and metastasis in human colorectal cancer
(CRC) cohorts by analysis of gene expression profiles. PDGFRB expression in primary CRC was correlated with short
disease-free and overall survival. PDGFRB was co-expressed with genes involved in platelet activation, transforming
growth factor beta (TGFB) signaling, and EMT in three CRC cohorts. PDGFRB was expressed in mesenchymal-like
tumor cell lines in vitro and stimulated invasion and liver metastasis formation in mice. Platelets, a major source of
PDGF, preferentially bound to tumor cells in a non-activated state. Platelet activation caused robust PDGFRB tyrosine
phosphorylation on tumor cells in vitro and in liver sinusoids in vivo. Platelets also release TGFB, which is a potent
inducer of EMT. Inhibition of TGFB signaling in tumor cells caused partial reversion of the mesenchymal phenotype
and strongly reduced PDGFRB expression and PDGF-stimulated tumor cell invasion. These results suggest that
PDGFRB may contribute to the aggressive phenotype of colorectal tumors with mesenchymal properties, most likely
downstream of platelet activation and TGFB signaling.
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Introduction
Multiple receptor tyrosine kinases and their growth factor ligands
have been implicated in cancer progression and metastasis. Among
these are the platelet-derived growth factor receptors (PDGFRs) [1].
Stimulation of the PDGFR leads to activation of intracellular signal-
ing pathways that can promote cell migration, invasion, survival, and
proliferation [2,3].
Expression of PDGFRs is mainly restricted to mesenchymal cell types
[2]. Activating mutations in PDGFRs are found in gastrointestinal stro-
mal tumors [1]. In colorectal carcinomas, PDGFR expression appears
to be mainly expressed by stromal cells and pericytes [4,5]. However,
PDGFRB can also be expressed by colorectal tumor cell lines [3,6], sim-
ilar to the mesenchymal marker vimentin [7]. We have recently shown
that PDGFRB primarily signals invasion in colorectal tumor cells [3]. In
line with this, PDGFR signaling contributes to the aggressive behavior
of other epithelial tumor types such as breast, liver, and pancreas car-
cinomas [8–10]. High PDGFR expression correlates with advanced
stage disease and poor prognosis in all these tumor types [6,8–11].
While most epithelial tumor cells do not express PDGFRs, they
may acquire PDGFR expression following epithelial-to-mesenchymal
transition (EMT) [12–19]. EMT is thought to contribute to metas-
tasis formation in multiple tumor types by generating tumor cells
with decreased cell-cell adhesion and enhanced invasive and clono-
genic properties [20]. In breast cancer, circulating tumor cells with a
mesenchymal-like phenotype are associated with poor survival [21–
23]. Breast and lung cancer cells acquire PDGFR expression following
EMT, which is essential for their metastatic potential [18,24]. A promi-
nent inducer of EMT is transforming growth factor beta (TGFB) [20].
Recently, it was shown that TGFB stimulation of colorectal cancer
(CRC) cells promotes invasive mesenchymal-like growth of murine
colorectal tumor cells and increased metastatic capacity [25]. A po-
tential role for the PDGFR was not investigated in that study. Taken
together, the above studies suggest that PDGFR expression, like EMT,
could be a transient phenomenon that may facilitate the metastatic
process. This could play a role at the primary tumor site but also in
the circulation and/or at the secondary organ site.
Disseminated tumor cells are surrounded by platelets, which are a
major source of PDGF [2]. Tumor cell–associated platelet aggregation
and microthrombus formation occurs when tumor cells get trapped in
the microvasculature of the distant organ [26–30]. This can be medi-
ated by cancer-specific mucins that contain multiple binding sites
for platelets, leukocytes, and endothelial cells [31]. Once activated,
platelets promote metastasis formation by releasing specific growth
factors, including lysophosphatidic acid and TGFB [25,32–34]. In
line with their prominent pro-metastatic activity, high platelet counts
are associated with poor prognosis in many cancer types, including
CRC [32,35,36].
In the present report, we show that PDGFRB expression in human
CRC is strongly correlated with platelet activation, TGFB signaling,
and EMT.We also show that PDGFRB signaling in mesenchymal-like
tumor cells contributes to invasion and liver metastasis formation.
Materials and Methods
Bioinformatic Analyses
Most analyses were performed using the R2 microarray analysis and
visualization platform (http://r2.amc.nl). Expression of PDGFR and
epithelial growth factor receptor (EGFR) across data sets was done
by choosing the “Megasampler” option in R2 and selecting all nine
colorectal tumor data sets.
Disease-free survival (DFS) data are available for three of the data
sets (Jorissen et al. [37], Smith et al. [38], and Snoeren et al. [39]).
In addition, two data sets contain overall survival (OS) data (Smith
et al. and Snoeren et al.). The association of PDGFRB expression with
DFS and OS was determined by using the Kaplan-Meier option in R2.
Median PDGFR expression levels were used as cutoff values. P values
were determined by log-rank test as described in Bewick et al. [40].
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway anal-
ysis was performed by choosing the “KEGG Pathway Finder” option
and setting the single gene association (Pearson correlation) P values
to <E−10 (P value determined by t = r/sqrt((1 − r2)/(n − 2)), distrib-
uted approximately as t with n − 2 degrees of freedom) for each of the
three data sets. The KEGG pathways that were significantly (P < .01
chi-square goodness-of-fit test) enriched in at least two of three lists of
PDGFR-associated genes were then identified and ordered according
to significance, based on the combined P values (Stouffer z-trend) that
were calculated with theWeb-basedMetaP application (http://compute1.
lsrc.duke.edu/softwares/MetaP/metap.php). A similar approach was used
to identify GeneOntology (GO) terms significantly enriched in the sets of
PDGFR-associated genes. Here, the P values for single gene associations
was set to <E−7 for each data set.
Genes that were significantly associated with PDGFRB within each
of the identified KEGG pathways (P < .01; chi square goodness of fit
test) were identified by making use of the KEGG pathway gene filter
option in R2. GeneVenn was then used to identify subsets of genes
showing significant association with PDGFR expression in at least
two of three data sets. The functional interconnectivity between the
genes in these lists was visualized using the STRING tool for known
and predicted protein-protein interactions (www.string-db.org). The
lists were reimported into R2 to generate heat maps in which the tu-
mors were ordered according to PDGFR expression levels from low to
high using the largest data set available (Jorissen et al.; 290 tumors).
All human experiments were carried out with informed consent of
the volunteers and under approval and accordance with the guidelines
of the Medical Ethical Committee of the University Medical Center
Utrecht (Utrecht, The Netherlands).
Cell Culture
C26 and MC38 murine colorectal tumor cells were cultured
in Dulbecco’s modified Eagle’s medium (Dulbecco, ICM Pharma-
ceuticals, Costa Mesa, CA) supplemented with 5% (vol/vol) fetal calf
serum (FCS), 2 mM ultraglutamine, 0.3 mg/ml streptomycin, and
100 U/ml penicillin. Cells were kept at 37°C in a humidified atmo-
sphere containing 5% CO2.
C26 luciferase were described before [41]. C26GFP and MC38GFP
cell lines were generated by lentiviral transduction using pWPT–green
fluorescent protein (GFP; a kind gift from D. Trono).
Antibodies and Reagents
The following antibodies were obtained fromCell SignalingTechnol-
ogy, Inc (Beverly, MA): rabbit pY1021-PDGFRB (#2227) and rabbit
PDGFRB (#4564); from BD Pharmingen (Breda, The Netherlands):
PE-Cy5 mouse CD42b (551141), PE mouse P-selectin (Cd62P)
(#555524), rat CD41 (#553847), mouse N-cadherin (#610920),
mouse Fibronectin (#610077), rabbit active caspase-3 (#559565); from
Santa Cruz Biotechnology, Inc (Santa Cruz, CA): rabbit pY1021-
PDGFRB (sc-12909-R); from Thermo Fisher Scientific (Amsterdam,
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The Netherlands): rabbit KI67 (rm-9106-s); from Sigma-Aldrich
(Zwijndrecht, The Netherlands): PDGFRB (HPA028499); from
Emfret Analytics (Eibelstadt, Germany): rat anti-mouse P-selectin
(#M130-2). Secondary peroxidase-conjugated antibodies were from
Dako (Heverlee, Belgium). The following reagents were used in this
study: PDGF-BB (PGM0044; Invitrogen, Bleiswijk, TheNetherlands),
TGFB1 (H8541; Sigma-Aldrich), thrombin receptor–activating
peptide (TRAP, SFLLRN; Bachem AG, Bubendorf, Switzerland),
prostaglandin I2 (PGI2) analog iloprost (Ilomedine; Bayer Schering
Pharma AG, Berlin, Germany), collagen-related peptide (CRP) gener-
ated as described earlier [42], and SB431524 (#S4317; Sigma-Aldrich).
Short interfering RNA (siRNA) OTP SMARTpools from Dharmacon
(Amsterdam, The Netherlands) were transfected using reverse trans-
fection with Hiperfect (Qiagen, Venlo, The Netherlands) according
to the manufacturers’ guidelines. Gene names and siRNA sequences
of the siRNA library are listed in Figure W4C .
Platelet Isolation
Human platelets were isolated as previously described [43]. In
short, fresh whole blood was drawn from healthy volunteers into 3.2%
trisodium citrate tubes (Greiner Bio-One GmbH, Frickenhausen,
Germany). Platelet-rich plasma was prepared within 1 hour after col-
lection by centrifugation at 160g for 15 minutes at 20°C. Subsequently,
0.1 volume of acid citrate dextrose (containing 2.5% trisodium citrate,
1.5% citric acid, and 2% D-glucose) was added to lower the pH to
6.5. Platelet-rich plasma was spun down by centrifugation at 340g
for 15 minutes at 20°C. The platelet pellet was resuspended in Hepes-
Tyrode buffer (containing 145 mM NaCl, 5 mM KCl, 0.5 mM
Na2HPO4, 1 mM MgSO4, 10 mM Hepes, and 5 mM D-glucose,
pH 6.5). Prostacyclin (PGI2; Cayman Chemical Company, Ann Arbor,
MI) was added to a final concentration of 10 ng/ml and platelets
were spun down at 340g for 15 minutes at 20°C. The pellet was resus-
pended in Hepes-Tyrode buffer (pH 7.2) at a platelet count of 2.0 ×
1011 platelets/l. Platelets were allowed to return to a resting state for
at least 30 minutes before usage.
Tumor Cell Platelet Binding
GFP-expressing tumor cells were harvested by brief trypsinization,
washed, and suspended in Hepes-Tyrode buffer to a final concentra-
tion of 1 × 105 cells/ml. To exclude clumps of cells, the mixture was
passed through a 40-μm cell strainer. Tumor cells and platelets were
mixed in a 1:10 ratio and incubated for 30 minutes at room tempera-
ture. Hereafter, blocking was performed with FCS after which cells
were washed with Hepes-Tyrode buffer by centrifugation at 400g for
10 minutes. Antibody binding (1:50) was allowed in Hepes-Tyrode
buffer. After 30 minutes at room temperature, the cell platelet suspen-
sion was washed and resuspended in Hepes-Tyrode buffer containing
2% formaldehyde. Cells were analyzed using flow cytometry.
Flow Cytometry
The expression of a panel of cell surface markers was analyzed using
a FACSCalibur (BD, Franklin Lakes, NJ). All antibody incubation
steps were carried out at room temperature. GFP-expressing tumor
cells were used and selected on fluorescent intensity. Doublets and
clumps of tumor cells were excluded by size using doublet discrimi-
nation gating. For analysis of inactive platelets, PE-Cy5 anti-CD42b
was used. For analysis of active platelets, PE anti–P-selectin was used
as a marker. All samples were analyzed by bivariate flow cytometry
using Cell Quest software (BD).
Western Blot Analysis
Western blot analysis was performed exactly as described before
[41,44].
Invasion Assay
For in vitro invasion assays, 24-well BioCoat Matrigel invasion
chambers (#354480; BD), with an 8-μm pore PET membrane coated
with Matrigel basement membrane matrix, were used according to the
manufacturer’s protocol. Cells were kept under serum-free conditions
overnight. In the upper compartment, 5 × 104 cells/well were plated
onto 0.5 ml of serum-free medium. The lower compartment contained
0.75 ml of medium with 0% FCS. PDGF (10 ng/ml) was added to
the upper and/or lower compartment. For inhibitor experiments, cells
were pretreated with 10 μg/ml SB431524 overnight before plating and
during the experiment in both the upper and lower compartments.
Invasion chambers were incubated for 8 hours at 37°C in a humidified
incubator with 5% CO2. Remaining cells in the upper compartment
were removed with a cotton swap. The transmigrated cells were fixed
in 3.7% formaldehyde, stained with 4′,6-diamidino-2-phenylindole
(DAPI), and counted by analyzing microscopic images (five to six
fields per transwell membrane; magnification, ×10). Data are expressed
relative to control. All assays were performed in duplicate and were
repeated twice.
In Vitro Proliferation Assay
Cells (5000 cells/96-well plate) were plated and incubated at 37°C
in a humidified atmosphere containing 5% CO2. Proliferation was
analyzed every 24 hours for 4 days by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide assays (Roche Diagnostics, Basel,
Switzerland) according to the manufacturer’s instructions.
Immunohistochemistry
After harvesting, organs were either snap frozen in Tissue-Tek
OCT using liquid nitrogen or fixed in 4% paraformaldehyde and
paraffin embedded. Frozen tissue was sectioned using a Leica cryotome
CM3050 (Mannheim, Germany), fixedwith acetone, and an immuno-
staining was performed. Paraffin-embedded tissues were sectioned by a
Leica microtome RM 2235 and stained according to standard histology
protocols. For immunofluorescence, image acquisition and analysis was
performed using a Zeiss Axiovert 200M and Zeiss LSM 510 Software.
Animals and Surgery
Male Balb/c mice (10–12 weeks) were purchased from Charles River
(Wilmington, MA). Mice were housed under standard laboratory con-
ditions and received food and water ad libitum. All surgical procedures
were performed under isoflurane inhalation anesthesia. Before surgery,
buprenorfine was administered intramuscularly to provide sufficient
perioperative analgesia. All animal experiments were carried out in
accordance with the guidelines of the Animal Welfare Committee of
the University Medical Center Utrecht.
Liver Metastasis Mouse Model
C26 cells expressing GFP or luciferase were harvested by brief
trypsinization. Colorectal liver metastases were induced as previously
described [45,46]. In brief, single cell suspensions were prepared in
phosphate-buffered saline to a final concentration of 7.5 × 104 cells/
100 μl. Cells were injected into the parenchyma of the spleen. Ten
minutes after injection, the spleen was removed. Induction and
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bioluminescence imaging of colorectal liver metastases was performed
as described [41].
Hepatic Replacement Area
Tumor load in the liver was assessed in all liver lobes. Tumor load
was scored as hepatic replacement area (HRA), that is, the percentage of
liver tissue that had been replaced by tumor tissue, exactly as described
before [47].
In brief, on hematoxylin and eosin–stained sections, at least 100 fields
were selected using an interactive video overlay system, including an
automated microscope (Q-Prodit; Leica Microsystems) at a ×40 mag-
nification. Using a four-point grid overlay, the ratio of tumor cells versus
normal hepatocytes was determined for each field. Tumor load (HRA)
was expressed as the average area ratio of all fields.
Statistical Analysis
Statistical differences between groups were analyzed by an unpaired
two-sided t test. Data are expressed as means ± SEM. A P value of
<.05 was considered statistically significant (indicated by an asterisk).
Results
PDGFRB Expression in Primary CRC Is Associated with
Poor Prognosis
Our previous results have implicated PDGFR signaling in the inva-
sion of colorectal tumor cells in vitro [3]. Very little is known about
the impact of PDGFR signaling on human colorectal tumor behavior.
We first analyzed gene expression profiles of nine different tumor
Figure 1. Expression of PDGFRB in human CRC. (A) mRNA levels of PDGFRB and EGFR of all tumors from nine different cohorts were
plotted. With the exception of one adenoma cohort, PDGFRB is expressed at considerable levels in multiple CRC cohorts. (B) Immuno-
histochemistry analysis of the expression of PDGFRB in human colorectal tumors. Examples of tumors are shown in which PDGFRB is pre-
dominantly expressed in stromal cells (left upper panel) in both tumor cell and stromal compartments (left lower panel) and in tumor cells only
(right upper and lower panels). Red arrowheads indicate expression in stromal tissue. White arrowheads indicate expression in tumor tissue.
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Figure 2. PDGFRB expression in primary CRC is associated with shorter DFS and OS. (A) Expression levels of PDGFRB and EGFR were
correlated with OS in a cohort of 232 primary CRCs [38]. Median expression was used as a cutoff. Kaplan-Meier curves show that
expression of PDGFRB, but not EGFR, is associated with a significantly shorter OS. (B) Expression levels of PDGFRB were correlated
with DFS in a cohort of 232 primary CRCs [38] and a cohort of 290 primary CRCs [37]. Median expression was used as a cutoff. Kaplan-
Meier curves show that expression of PDGFRB is associated with shorter DFS in both cohorts. (C) A possible correlation between
PDGFRB levels with OS and DFS was analyzed in a cohort of 119 colorectal liver metastases [39]. Median expression was used as a
cutoff. Kaplan-Meier curve shows that expression of PDGFRB is not significantly associated with shorter survival.
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cohorts to assess whether PDGFRB expression would be associated
with clinical outcome. Figure 1A shows that PDGFRB and EGFR
are expressed at considerable levels in colorectal tumors, although a
direct comparison of the expression levels of both receptor tyrosine
kinases is not possible based on microarray data. One cohort of colo-
rectal adenomas (T Colon 32 (Marra)) shows considerable less ex-
pression of PDGFRB. Immunohistochemistry staining for PDGFRB
in CRC specimens demonstrated the expected stromal staining (Fig-
ure 1B). In addition, PDGFRB expression was also clearly observed in
the tumor cells of 8 of 10 human CRC tumors (Figures 1B and W1).
We next assessed whether PDGFRB expression was correlated with sur-
vival in two cohorts of 232 and 290 primary CRC tumors [37,38] and
Table 1. Pathway Analysis of Genes Co-expressed with PDGFRB in CRC.
P Value, Snoeren et al. P Value, Smith et al. P Value, Jorissen et al. P Value, Combined
KEGG pathway
ECM-receptor interaction 4.20E−12 3.90E−32 8.10E−15 3.33E−50
Focal adhesion 2.20E−10 5.70E−24 5.40E−11 1.42E−37
Malaria 7.90E−05 3.30E−15 5.40E−08 3.07E−23
Complement and coagulation cascades 1.30E−04 1.50E−08 7.10E−06 3.56E−15
Glycosaminoglycan biosynthesis 2.00E−02 2.80E−09 6.40E−06 2.97E−14
Amebiasis 7.50E−05 1.10E−10 1.30E−03 1.08E−13
Phagosome 1.00E−02 1.00E−08 1.20E−04 1.76E−12
Leukocyte transendothelial migration 2.00E−02 1.50E−06 1.90E−05 1.47E−11
Cell adhesion molecules 4.00E−02 1.10E−04 1.50E−03 1.25E−07
Regulation of actin cytoskeleton 3.00E−02 1.10E−04 7.30E−03 7.23E−07
Vascular smooth muscle contraction 2.00E−03 5.40E−03 2.00E−02 1.54E−05
TGFB signaling pathway 4.40E−05 4.60E−03 7.00E−02 1.95E−05
GO pathway
ECM 8.9E−44 1.4E−98 6.8E−27 5.2E−135
PDGF binding 2.7E−22 2.3E−18 4.5E−8 2.7E−34
Platelet activation 7.2E−9 5.1E−10 1.2E−9 1.9E−23
Platelet alpha-granule 2.2E−6 3.7E−13 1.2E−6 7.2E−21
Platelet degranulation 2.9E−3 3.8E−10 2.4E−9 1.2E−19
TGFB signaling pathway 4.4E−6 4.1E−4 1.7E−7
PDGFRB-associated genes in each separate tumor cohort were analyzed for overrepresentation ofKEGGpathways andGO terms by using R2. All KEGGpathways significantly associatedwith PDGFRB expression
in at least two of three data sets are shown. A limited set of GO terms that are related to those KEGG pathways is shown in addition. Combined P values were calculated with the Web-based MetaP software.
Figure 3. Co-expression of PDGFRBwith genes governing ECM-receptor interaction, platelet activation, TGFB pathway, and EMT in colorectal
tumors. Heat map of the expression of genes co-expressed with the PDGFR in at least two of three tumor cohorts in the categories “ECM-
Receptor Interaction,” “Platelet Activation,” “Platelet alpha-Granule,” “TGFB pathway,” and “EMT.” The overlapping genes were identified by
GeneVenn (Figure W1). An overview of the individual genes in these categories and their correlation with PDGFRB is presented in Table W1.
Neoplasia Vol. 15, No. 2, 2013 PDGFRB Promotes Liver Metastasis Formation Steller et al. 209
a cohort of 119 liver metastases [39]. Using mean PDGFR levels as the
cutoff value, we found that high PDGFRB expression in primary CRC
tumors was correlated with shorter DFS and OS (Figure 2, A and B).
This was not observed in liver metastases (Figure 2C).
PDGFRB Expression Is Associated with Extracellular
Matrix–Receptor Signaling, Platelet Activation,
TGFB Signaling, and EMT
We next used bioinformatics tools of the R2 Web application
(http://r2.amc.nl) to search for processes, pathways, and single genes
associated with expression of PDGFRB in CRC. Searching the KEGG
pathway database revealed seven pathways that were significantly asso-
ciated with PDGFRB expression in the three separate tumor cohorts
(Table 1). These include “Extracellular Matrix–Receptor Interaction,”
“Coagulation,” and “TGFB signaling.” Within the “ECM-Receptor”
pathway, 46 genes were significantly correlated with PDGFRB in
at least two of three tumor cohorts (Figure W2A; P = 6.7E−76). This
gene set contains 15 collagens, 6 laminins, 8 integrins, and 4 thrombo-
spondins (Table W1 and Figure W2A). All of the genes in this cate-
gory were positively (rather than negatively) correlated with PDGFRB
expression (Figure 3).
We noted that many of the genes within the extracellular matrix
(ECM)–Receptor class promote platelet activation, including collagens,
laminins, thrombospondins, von Willebrand factor, and fibronectin
(Table W1). GO analysis of the genes co-expressed with PDGFRB in
the separate tumor cohorts revealed that “Platelet Activation,” “Platelet
alpha-granule,” and “Platelet Degranulation” were indeed significantly
overrepresented in all three cohorts (Table 1; P = 1.9E−23). We iden-
tified a set of 41 “Platelet activation” genes that were significantly cor-
related with PDGFR expression in at least two of three tumor cohorts.
All of these correlations were positive (Table W1 and Figure W2B). In
addition, all except one (ALDOA) “Platelet alpha-granule” genes were
positively correlated with PDGFRB expression (Figure 3).
Platelet activation promotes the metastatic capacity of tumor cells
[32]. TGFB signaling has recently been identified as a major platelet-
released pro-metastatic growth factor in a model of colorectal metastasis
formation [25]. TGFB signaling was also one of the seven KEGG path-
ways that were significantly associated with PDGFRB expression in all
three tumor cohorts (Tables 1 and W1 and Figure W2C ; P = 1.2E−8).
A set of 28 overlapping “TGFB pathway genes” was identified of
which 22 were positively correlated with PDGFRB, including TGFB1,
TGFB2, TGFB3, and TGFB receptor 1 (TGFBR1). Mapping the
PDGFRB–co-expressed genes on a TGFB pathway image shows enrich-
ment of ligands, receptors, and signaling intermediates (Figure W3).
TGFB stimulation of epithelial tumor cells may lead to the acqui-
sition of a more mesenchymal phenotype, which is associated with in-
creased invasion and metastatic potential. Moreover, activated platelets
promote EMT in tumor cells by secreting TGFB [25] that stimu-
lates expression of the core transcription factors that mediate EMT
(SNAI1, SNAI2, ZEB1, ZEB2, TWIST1, and TWIST2; [48]). There-
fore, we next analyzed whether PDGFRB expression would be associ-
ated with these EMT-driving transcription factors. Indeed, PDGFRB
was strongly associated with all six EMT-inducing transcription fac-
tors and with mesenchymal genes, such as vimentin and N-cadherin
(CDH2; Table W1 and Figure 3). Conversely, PDGFRB was nega-
tively correlated with epithelial genes, including E-cadherin (CDH1),
plakophilin-2, and occludin (Table W1).
PDGFRB in Colorectal Tumor Cells Signals Invasion and
Metastasis Formation
The above results link PDGFRB expression to platelet activation,
TGFB signaling, EMT, and poor survival in human CRC. To test the
function of PDGFRB in CRC cells, we performed Matrigel Transwell
assays using PDGF-responsive C26 and MC38 CRC cells. Checker-
board analysis revealed that PDGF strongly promotes directed tumor
cell migration (chemotaxis), whereas non-directed migration (chemo-
kinesis) was not affected (Figure 4A). PDGF stimulation did not affect
the growth rate of MC38 or C26 cells (Figure W4A).
Next, we assessed the contribution of PDGFRB to liver metastasis for-
mation. To this end, PDGFRB expression was suppressed by transfecting
siRNAs into C26 cells expressing firefly luciferase. This resulted in effi-
cient suppression of PDGFRB expression over a period of at least 4 days
(FigureW5A). Expression levels returned to normal 6 days after transfec-
tion (Figure W5B). C26-siPDGFRB and control cells expressing scram-
bled siRNAs were injected into the spleens of syngeneic Balb/c mice 2
days after transfection. Bioluminescence imaging over time showed that
PDGFRB knockdown significantly reduced the outgrowth of liver me-
tastases (Figure 4B). After 13 days, the livers were removed and the HRA
(percentage of liver tissue occupied by tumor) was analyzed. PDGFRB
knockdown had caused a significant drop in metastatic load
(Figure 4B). Immunohistochemistry for active caspase-3 and KI67 on tu-
mor tissue sections showed that suppression of PDGFRB expression had
no effect on apoptosis or proliferation in liver metastases (Figure 4C).
Likewise, PDGFRBknockdown had no effect on the in vitro growth rate
of C26 or MC38 cells (Figure W4B).
ALK5 Inhibition Reduces PDGFRB Expression and
PDGF-Stimulated Invasion
The above results show that PDGFRB promotes invasion and liver
metastasis formation. The C26 and MC38 cells that were used in
this study display mesenchymal features including low expression of
Figure 4. PDGFRB stimulates invasion and liver metastasis formation in CRC cell lines. (A) C26 and MC38 cells were cultured in transwell
chambers, and invasion through Matrigel was assessed following addition of PDGF-BB (10 ng/ml; 8 hours) to the insert (top) or to the
well (bottom) of the invasion chamber. All conditions were tested in duplicate in two independent experiments. Numbers represent fold
change of the number of invaded cells relative to control (no PDGF-BB in either compartment). (B) C26 cells expressing luciferase and
either siRNAs targeting PDGFRB or control siRNAs were injected into the splenic parenchyma followed by splenectomy. The formation
of liver metastases was then followed over time using bioluminescence imaging. Representative bioluminescence images of liver me-
tastasis formation over time are depicted (scale bar represents bioluminescence counts). Two weeks after tumor cell injection, the livers
were harvested and the HRA (liver area occupied/replaced by tumor tissue) was determined morphometrically (n = 7 mice per group).
(C) Sections of the livers harvested in B were analyzed for the presence of apoptotic caspase-3–positive cells (left panel; white arrow-
head indicates active caspase-3–positive cell) and proliferating Ki67-positive cells (right panel; black arrowhead indicates Ki67-negative
cell) by immunohistochemistry. The bar graphs show the percentage positive cells measured in five high-power fields per mouse in six
mice per condition. All error bars represent SEM. Significance was tested using Student’s t test (unpaired; double sided).
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E-cadherin and high expression of N-cadherin and fibronectin (Fig-
ure 5A). Inhibition of constitutive TGFB signaling in C26 cells has
previously been shown to lead to loss of the mesenchymal phenotype
and to a concomitant loss of metastatic potential [49]. Indeed, treatment
with the ALK5 inhibitor SB431524 blocked TGFB signaling in
these cells (Figure W6) and strongly reduced basal fibronectin and
N-cadherin expression, although this was not accompanied by re-
expression of E-cadherin (Figure 5A). Importantly, ALK5 inhibition
reduced PDGFRB expression and PDGF-stimulated tumor cell invasion
(Figure 5,A andB), indicating that PDGFRB expression and signaling in
these cells requires TGFB signaling.
PDGF from Platelets Activates the PDGFRB on Tumor Cells
Circulating platelets are a major source of PDGF and have strong
pro-metastatic activity [2,32]. Therefore, we assessed whether PDGF
from platelets could stimulate the PDGFRB expressed on tumor
cells. To this end, C26 and MC38 cells were exposed to PDGF or
to platelets. Platelets were isolated from blood and were either left
unstimulated or pre-stimulated with TRAP. As expected, PDGF
caused rapid tyrosine phosphorylation of the PDGFRB on C26 cells
(Figure 6A). Non-stimulated platelets also induced some PDGFRB
phosphorylation on C26 and MC38 cells, but this was drastically
increased when platelets were pre-activated (Figure 6, B and C ).
The time course of PDGFRB activation with (activated) platelets
was similar to that induced by purified PDGF.
Tumor Cells Preferentially Bind Inactive Platelets
Next, we used flow cytometry to study a potential interaction be-
tween tumor cells and platelets. Inactive platelets were isolated from
donor blood andmixed with GFP-expressing tumor cells in a 10:1 ratio.
Of all GFP-positive C26 and MC38 cells, 30% to 40% were also pos-
itive for the platelet marker CD42b (Figures 7A and W7B). Addition-
ally, 5% to 10% of tumor cells were also positive for P-selectin, a marker
for activated platelets (Figures 7A and W7B). Activation of platelets
with TRAP before mixing with tumor cells did not change the total per-
centage of platelet–tumor cell events. Although 95% of the platelets
Figure 5. The ALK5 inhibitor SB431524 suppresses PDGFRB expression and PDGF-stimulated invasion. (A) C26 cells were incubated with
SB431524 (10 ng/ml) or vehicle for 1 week. Cells were lysed and expression of PDGFRB, N-cadherin, fibronectin, E-cadherin, and actin was
assessed byWestern blot analysis. (B) C26 cells were cultured in transwell chambers and invasion throughMatrigel was assessed following
addition of PDGF-BB (10 ng/ml; 8 hours) to the bottom well of the invasion chamber, in the presence or absence of SB431524 (10 ng/ml). All
conditions were tested in triplicate in two independent experiments. Numbers represent fold change of the number of invaded cells relative
to control (no PDGF-BB added). All error bars represent SEM. Significance was tested using Student’s t test (unpaired; double sided).
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were activated (Figure W7A), the majority of tumor cell–bound plate-
lets were inactive (Figures 7A and W7B). Prevention of platelet activa-
tion by treatment with iloprost did not change the total percentage
of platelet-bound tumor cells but reduced the number of activated
platelet–tumor cell events to undetectable levels (Figures 7A and
W7B). Together, these results suggest that tumor cells preferentially
bind inactive platelets.
PDGFRB Phosphorylation on Platelet-Covered Tumor Cells
in the Liver Sinusoids
To study the platelet–tumor cell interaction in vivo, C26-GFP cells
were injected into the spleen and the livers were harvested 2 hours
after injection. Immunofluorescence microscopy confirmed intra-
sinusoidal localization of GFP-positive tumor cells (Figure 7B). Co-
staining with CD41 showed that approximately 52% of all green tumor
cells were surrounded by platelets. These cells also showed tyrosine
phosphorylation of the PDGFRB (Figure 7B). By contrast, tumor cells
that were not surrounded by CD41-positive platelets were negative for
PDGFRB phosphorylation.
Activation of Platelets in Complex with Tumor Cells
To investigate if tumor cell–associated platelets are still responsive
to activation by ECM components, tumor cells were mixed with
isolated platelets. To mimic ECM exposure, CRP was added to the
mixture and flow cytometry was used to study activation of platelets
on platelet–tumor cell complexes. Approximately 40% of all tumor
cells were covered by platelets, of which 8% was also positive for
p-Sel. Thus, ∼20% of tumor cell–bound platelets was activated (Fig-
ure 7C). After exposure to CRP, the percentage of platelet–tumor cell
complexes positive for P-selectin increased to ±45% (Figure 7C). This
Figure 6. Activation of PDGFRB on CRC cell lines by activated platelets. C26 cells were cultured in serum-free medium overnight and were
subsequently stimulated with purified 5 ng/ml PDGF-BB for different lengths of time (A), with 625 μM TRAP alone, or with platelets (25 ×
106/ml) that had been pre-activated or not (B). Platelet activation was performed by exposing them to 625 μM TRAP. The same experi-
ment was performed using MC38 cells (C). Stimulus-induced changes in expression and tyrosine 1021 phosphorylation of PDGFRB
(pY1021-PDGFRB) was analyzed over time (0–10 minutes) by Western blot analysis.
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indicates that platelets associated to tumor cells are still responsive to
activation by ECM components such as collagen.
Next, we analyzed C26-GFP tumor cells arrested in mouse liver
sinusoids 2 hours after intrasplenic injection for P-selectin positivity
by immunofluorescence (Figure 7D). Of 208 arrested tumor cells,
105 (∼50%) were also positive for P-selectin (Figure 7D), similar to
the total percentage of platelet-covered tumor cells (52%, Figure 7B).
Together, these results indicate that platelets in complex with tumor
cells are activated following tumor cell lodging in the sinusoids and that
this may be mediated by exposure to ECM components.
Discussion
In the present report, we provide evidence that mesenchymal-like
colorectal tumor cells express PDGFRB that stimulates invasion and
contributes to the metastatic capacity of such cells. Mounting evidence
suggests that epithelial cells have to undergo EMT to efficiently seed
metastases [18,20,50,51]. In a mouse model for spontaneous metastatic
pancreas carcinoma, the metastasizing tumor cells undergo EMT tran-
siently and revert back to an epithelial phenotype in the distant organ
[50]. Furthermore, recent studies in breast cancer patients have shown
that a subpopulation of circulating tumor cells indeed has mesenchymal
features and that high numbers of such cells predict poor prognosis
[50,52–55]. The transient nature of EMTmay explain why this pheno-
menon is hard to detect by immunohistochemistry on human tumor
tissue sections. In addition, epithelial tumor cells with mesenchymal
properties are distinct from true mesenchymal cells and may be hard
to discriminate morphologically from their epithelial neighbors on tis-
sue sections. Indeed, a considerable proportion of human colorectal
tumors express moderate to high levels of the mesenchymal marker
vimentin in the tumor cells without appearing mesenchymal. This
was associated with the presence of nuclear B-catenin, which helps drive
the EMT-like process, but not with clear changes in epithelial mor-
phology [7]. Likewise, PDGFRB expression in colorectal tumor cells
has previously been documented [6]. In the current study, we show
that vimentin expression is strongly associated with PDGFRB ex-
pression and that this identifies an aggressive subset of CRC tumors
(Table W1). We found that high PDGFRB expression in primary
tumors correlates with tumor recurrence (metastasis formation) but also
that this association was not found in already established metastases.
Therefore, PDGFRB may primarily play a role in establishing distant
metastases rather than in promoting the growth of established lesions.
Although the contribution of stromal cells to gene expression pro-
files of colorectal tumors is relatively small [56], we cannot exclude that
stromal cells have contributed to PDGFRB expression in our analyses
of the human tumor cohorts. Whatever that contribution may be,
there is no doubt that EMT of tumor cells from diverse epithelial
origins generates PDGFRB-expressing tumor cells with mesenchymal
properties [12–14,16,18,24] (this study). Importantly, such cells
become dependent on PDGFR signaling for efficient metastasis for-
mation [18,24]. Expression of the PDGFRB in epithelial tumor cells
is stimulated by TGFB [18,24] and by the EMT-driving transcription
factor SNAIL [57]. Indeed, PDGFRB expression in CRC was strongly
correlated with both TGFB signaling and with key EMT-driving tran-
scription factors. Furthermore, inhibition of TGFB signaling reduced
PDGFRB signaling in mesenchymal-like CRC cells (this study) and
suppressed metastasis formation [49]. Vice versa, restoration of TGFB
receptor signaling in human epithelial colorectal tumor cells with a
mutation in TGFBR2 greatly enhanced tumor cell invasion [49].
EMT induced by TGFB or SNAIL results in enhanced expression
of PDGFRB and ECM genes including collagens and fibronectin [57–
59]. ECM deposition promotes platelet activation, which stimulates
the metastatic process [32–34]. However, it is less clear during which
steps in the metastatic cascade platelets may play a role. Most of the
available evidence supports a role for platelets during initial metastasis
Figure 7. Platelets bind tumor cells and cause PDGFRB activation on tumor cells lodged in the liver sinusoids. (A) GFP-expressing tumor
cells and platelets were mixed in a 1:10 ratio. Before mixing, platelets were non-treated, inactivated by iloprost (2 μM), or activated by TRAP
(2.5 μM) treatment as indicated. Two independent experiments were performed in duplicate. The fraction of tumor cells that were bound to
non-activated and activated platelets was then analyzed by flow cytometry for GFP, CD42b, and P-selectin. The white bars represent all
tumor cell (GFP)–platelet (CD42b+ve) events, whereas the gray bars represent tumor cell (GFP)–activated platelet (CD42b+ve; P-selectin+ve)
events. (B) GFP-expressing C26 tumor cells were injected into the spleen. After 2 hours, the liver was perfused with periodate-lysine-
paraformaldehyde (PLP), harvested, and processed for cryosectioning and immunofluorescence using anti–pY1021-PDGFRB (white) and
CD41 (red) antibodies and DAPI (blue). CD41-positive platelet clusters were observed around∼52%of all sinusoid-arrested single tumor cells.
These tumor cells were also positive for pPDGFRB. Representative images are shown. (C) Tumor cells were mixed with platelets exactly as
in A. Hereafter, the mixture was treated with CRP (10 μm/ml) as indicated. Two independent experiments were performed in duplicate.
The mixture was subsequently analyzed by flow cytometry exactly as described in A. (D) As in B, cryosections were processed for
immunofluorescence using anti–P-selectin (red) and DAPI (blue). P-selectin–positive tumor cells were identified surrounding∼50% of all
GFP-positive tumor cells. Representative images are shown; a tumor cell negative for P-selectin is indicated by asterisk.
Figure 8. Working model for PDGFR signaling in metastatic CRC.
Tumors with high ECM content, including collagens, fibronectin,
and tenascin-C, are prone to platelet activation. Activated platelets
produce TGFB that stimulates EMT and PDGFR expression in tumor
cells. Platelets also produce PDGF that can then stimulate tumor
cells and stromal cells in a paracrine fashion. Mesenchymal-like
tumor cells are invasion-prone and have a relatively high capacity
to seed distant metastases.
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establishment at distant sites. Microthrombi containing activated plate-
lets are formed around tumor cells that are trapped in the micro-
vasculature of the liver or the lungs [26–30] (this study). This may
help tumor cell extravasation and/or early establishment of novel meta-
static lesions. Interestingly, at least two key components of the meta-
static niche, fibronectin and tenascin-C, are also potent inducers of
platelet activation [60–63]. Furthermore, both ECM components are
co-expressed with PDGFRB in CRC (Table W1). Platelet activation
and subsequent EMT may also help tumor cells to detach from the
primary tumor to disseminate.
We propose that aggressive colorectal tumors with high expression
of PDGFRB and EMT genes may sustain their phenotype by high-
level matrix deposition resulting in an increased propensity for plate-
let activation. Activated platelets release TGFB that subsequently
promotes EMT and PDGFR signaling in tumor and stromal cells
(Figure 8). This self-sustaining series of events may operate both within
the primary tumor and at distant sites.
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Figure W1. Immunohistochemistry analysis of the expression of PDGFRB in 10 human colorectal tumors. In only two tumors, PDGFRB is
expressed in stromal cells only (A). In 8 of 10 tumors, the tumor cell compartment was predominantly positive, sometimes accompanied by
stromal staining (B).
Figure W2. Overlap between PDGFRB-associated genes from the three tumor cohorts in the ECM-receptor interaction pathway (A), the
platelet activation pathway (B), and the TGFB pathway (C) was identified by GeneVenn [1]. STRING analysis [2] was then used to visualize
the high functional interconnectivity between the genes in these categories.
Table W1. Genes Co-expressed with PDGFRB in CRC.
Genes Data Set
Snoeren et al. Smith et al. Jorissen et al. Combined
R Value P Value R Value P Value R Value P Value R Value
ECM-receptor interaction
COL5A1 0.636 4.95E−14 0.783 4.43E−48 0.882 1.16E−94 0.767
THBS2 0.775 2.18E−23 0.694 6.04E−34 0.817 4.52E−70 0.762
LAMA4 0.660 6.84E−30 0.84 1.86E−77 0.750
COL5A2 0.674 4.98E−16 0.697 2.54E−34 0.873 1.66E−90 0.748
COL6A3 0.661 2.66E−15 0.726 1.95E−38 0.831 2.75E−74 0.739
COL4A2 0.66 2.29E−15 0.755 4.72E−43 0.725 6.54E−48 0.713
COL6A2 0.371 6.66E−05 0.848 1.02E−63 0.848 2.93E−80 0.689
COL5A3 0.682 1.90E−32 0.675 2.00E−39 0.679
COL6A1 0.404 1.20E−05 0.805 9.01E−53 0.825 1.26E−72 0.678
COL4A1 0.678 3.50E−16 0.611 1.16E−24 0.742 2.96E−51 0.677
ITGA5 0.729 7.89E−39 0.612 1.00E−30 0.671
COL1A2 0.553 2.92E−10 0.717 4.03E−37 0.699 3.36E−43 0.656
COL3A1 0.684 2.43E−16 0.631 1.33E−26 0.644 7.70E−35 0.653
SDC2 0.479 1.09E−07 0.602 6.79E−24 0.84 1.76E−77 0.640
HSPG2 0.698 1.82E−34 0.56 4.75E−25 0.629
COL11A1 0.441 1.45E−06 0.620 1.44E−25 0.725 7.59E−48 0.595
LAMB2 0.482 9.09E−08 0.670 4.87E−31 0.579 4.61E−27 0.577
LAMC1 0.493 4.59E−08 0.538 1.92E−18 0.654 2.91E−36 0.562
FN1 0.415 6.56E−06 0.605 3.98E−24 0.642 1.34E−34 0.554
LAMA2 0.487 6.31E−15 0.61 1.45E−30 0.549
ITGB5 0.631 8.30E−14 0.525 1.79E−17 0.486 1.96E−18 0.547
TNC 0.496 1.60E−15 0.591 2.33E−28 0.544
COMP 0.417 5.86E−06 0.496 1.67E−15 0.673 3.65E−39 0.529
THBS4 0.466 1.14E−13 0.569 5.41E−26 0.518
ITGAV 0.452 6.79E−13 0.549 5.71E−24 0.501
ITGA11 0.606 1.47E−12 0.518 4.91E−17 0.374 5.51E−11 0.499
COL1A1 0.602 1.94E−12 0.450 9.17E−13 0.387 1.08E−11 0.480
THBS3 0.315 8.89E−04 0.554 1.09E−19 0.519 3.30E−21 0.463
THBS1 0.379 4.64E−05 0.422 3.13E−11 0.578 6.51E−27 0.460
IBSP 0.376 4.97E−09 0.54 4.34E−23 0.458
SPP1 0.365 1.39E−08 0.533 1.89E−22 0.449
ITGA4 0.342 1.13E−07 0.485 2.54E−18 0.414
SDC3 0.485 7.83E−08 0.351 5.53E−08 0.381 2.38E−11 0.406
CD36 0.287 1.04E−05 0.481 5.47E−18 0.384
VWF 0.252 9.88E−03 0.461 2.20E−13 0.437 8.03E−15 0.383
ITGB3 0.325 5.09E−07 0.425 5.08E−14 0.375
ITGA7 0.421 4.91E−06 0.348 7.14E−08 0.349 1.19E−09 0.373
SV2A 0.349 1.96E−04 0.386 1.27E−11 0.368
COL2A1 0.301 3.50E−06 0.391 6.30E−12 0.346
AGRN 0.309 1.98E−06 0.372 7.32E−11 0.341
LAMB1 0.326 5.59E−04 0.349 6.29E−08 0.265 5.05E−06 0.313
LAMA5 0.262 5.86E−05 0.335 5.72E−09 0.299
COL4A4 0.257 7.93E−05 0.308 9.90E−08 0.283
COL6A6 0.190 3.82E−03 0.289 5.66E−07 0.240
ITGA10 0.190 3.91E−03 0.288 6.51E−07 0.239
TNXB 0.274 2.58E−05 0.198 6.80E−04 0.236
Platelet activation
COL5A1 0.636 4.95E−14 0.783 4.43E−48 0.882 1.16E−94 0.767
THBS2 0.775 2.18E−23 0.694 6.04E−34 0.817 4.52E−70 0.762
LAMA4 0.660 6.84E−30 0.84 1.86E−77 0.750
COL5A2 0.674 4.98E−16 0.697 2.54E−34 0.873 1.66E−90 0.748
COL6A3 0.661 2.66E−15 0.726 1.95E−38 0.831 2.75E−74 0.739
COL4A2 0.66 2.29E−15 0.755 4.72E−43 0.725 6.54E−48 0.713
COL6A2 0.371 6.66E−05 0.848 1.02E−63 0.848 2.93E−80 0.689
COL5A3 0.682 1.90E−32 0.675 2.00E−39 0.679
COL6A1 0.404 1.20E−05 0.805 9.01E−53 0.825 1.26E−72 0.678
COL4A1 0.678 3.50E−16 0.611 1.16E−24 0.742 2.96E−51 0.677
ITGA5 0.729 7.89E−39 0.612 1.00E−30 0.671
COL1A2 0.553 2.92E−10 0.717 4.03E−37 0.699 3.36E−43 0.656
COL3A1 0.684 2.43E−16 0.631 1.33E−26 0.644 7.70E−35 0.653
SDC2 0.479 1.09E−07 0.602 6.79E−24 0.84 1.76E−77 0.640
HSPG2 0.698 1.82E−34 0.56 4.75E−25 0.629
COL11A1 0.441 1.45E−06 0.620 1.44E−25 0.725 7.59E−48 0.595
LAMB2 0.482 9.09E−08 0.670 4.87E−31 0.579 4.61E−27 0.577
LAMC1 0.493 4.59E−08 0.538 1.92E−18 0.654 2.91E−36 0.562
FN1 0.415 6.56E−06 0.605 3.98E−24 0.642 1.34E−34 0.554
LAMA2 0.487 6.31E−15 0.61 1.45E−30 0.549
ITGB5 0.631 8.30E−14 0.525 1.79E−17 0.486 1.96E−18 0.547
TNC 0.496 1.60E−15 0.591 2.33E−28 0.544
COMP 0.417 5.86E−06 0.496 1.67E−15 0.673 3.65E−39 0.529
Table W1. (continued )
Genes Data Set
Snoeren et al. Smith et al. Jorissen et al. Combined
R Value P Value R Value P Value R Value P Value R Value
THBS4 0.466 1.14E−13 0.569 5.41E−26 0.518
ITGAV 0.452 6.79E−13 0.549 5.71E−24 0.501
ITGA11 0.606 1.47E−12 0.518 4.91E−17 0.374 5.51E−11 0.499
COL1A1 0.602 1.94E−12 0.450 9.17E−13 0.387 1.08E−11 0.480
THBS3 0.315 8.89E−04 0.554 1.09E−19 0.519 3.30E−21 0.463
THBS1 0.379 4.64E−05 0.422 3.13E−11 0.578 6.51E−27 0.460
IBSP 0.376 4.97E−09 0.540 4.34E−23 0.458
SPP1 0.365 1.39E−08 0.533 1.89E−22 0.449
ITGA4 0.342 1.13E−07 0.485 2.54E−18 0.414
SDC3 0.485 7.83E−08 0.351 5.53E−08 0.381 2.38E−11 0.406
CD36 0.287 1.04E−05 0.481 5.47E−18 0.384
VWF 0.252 9.88E−03 0.461 2.20E−13 0.437 8.03E−15 0.383
ITGB3 0.325 5.09E−07 0.425 5.08E−14 0.375
ITGA7 0.421 4.91E−06 0.348 7.14E−08 0.349 1.19E−09 0.373
SV2A 0.349 1.96E−04 0.386 1.27E−11 0.368
COL2A1 0.301 3.50E−06 0.391 6.30E−12 0.346
AGRN 0.309 1.98E−06 0.372 7.32E−11 0.341
LAMB1 0.326 5.59E−04 0.349 6.29E−08 0.265 5.05E−06 0.313
LAMA5 0.262 5.86E−05 0.335 5.72E−09 0.299
COL4A4 0.257 7.93E−05 0.308 9.90E−08 0.283
COL6A6 0.190 3.82E−03 0.289 5.66E−07 0.240
ITGA10 0.190 3.91E−03 0.288 6.51E−07 0.239
TNXB 0.274 2.58E−05 0.198 6.80E−04 0.236
TGFB pathway
THBS2 0.775 1.89E−23 0.694 5.05E−33 0.817 6.20E−69 0.762
DCN 0.810 4.87E−27 0.607 1.55E−23 0.747 1.16E−51 0.721
INHBA 0.639 6.83E−14 0.672 2.16E−30 0.774 1.51E−57 0.695
TGFB3 0.694 5.41E−17 0.626 2.20E−25 0.667 1.36E−37 0.662
TGFB1 0.549 1.02E−09 0.721 1.32E−36 0.704 2.53E−43 0.658
LTBP1 0.676 6.58E−16 0.461 9.92E−13 0.635 4.42E−33 0.591
COMP 0.417 1.66E−05 0.496 9.60E−15 0.673 1.76E−38 0.529
THBS3 0.315 2.57E−03 0.554 5.76E−19 0.519 1.22E−20 0.463
THBS1 0.379 1.41E−04 0.422 1.43E−10 0.578 3.08E−26 0.460
ID4 0.661 4.49E−15 0.260 2.29E−04 0.394 1.70E−11 0.438
ACVR1 0.314 2.48E−03 0.383 1.00E−08 0.564 8.02E−25 0.420
THBS4 0.172 6.00E−02 0.466 5.51E−13 0.569 2.37E−25 0.402
TGFBR1 0.272 2.80E−03 0.308 6.83E−06 0.545 5.12E−23 0.375
CDKN2B 0.361 3.28E−04 0.345 3.43E−07 0.385 4.63E−11 0.364
CHRD 0.164 7.00E−02 0.373 2.55E−08 0.386 4.30E−11 0.308
TGFB2 0.001 9.90E−01 0.374 2.39E−08 0.538 2.33E−22 0.304
FST −0.002 9.80E−01 0.478 1.15E−13 0.337 1.37E−08 0.271
INHBB 0.301 4.01E−03 0.247 5.13E−04 0.252 3.23E−05 0.267
BMPR1B −0.015 8.70E−01 0.363 6.13E−08 0.422 3.20E−13 0.257
BMP6 0.173 6.00E−02 0.236 8.89E−04 0.266 1.03E−05 0.225
BMPR2 0.007 9.40E−01 0.334 8.27E−07 0.323 5.83E−08 0.221
LEFTY2 0.027 7.70E−01 0.243 6.44E−04 0.374 1.77E−10 0.215
SMAD6 0.156 9.00E−02 −0.231 1.15E−03 −0.224 2.51E−04 −0.100
BMP5 0.126 1.70E−01 −0.328 1.32E−06 −0.203 9.49E−04 −0.135
SKP1 0.199 3.00E−02 −0.243 6.39E−04 −0.380 8.38E−11 −0.141
PPP2R1A −0.344 6.97E−04 0.041 5.40E−01 −0.286 2.21E−06 −0.196
PPP2CA −0.072 4.30E−01 −0.191 9.08E−03 −0.376 1.35E−10 −0.213
MYC −0.271 2.80E−03 −0.207 4.17E−03 −0.342 7.70E−09 −0.273
EMT
SNAI2 0.606 2.80E−13 0.815 4.30E−70 0.639 5.20E−28 0.687
ZEB2 0.687 6.50E−18 0.780 1.10E−60 0.539 6.50E−19 0.669
ZEB1 0.743 3.60E−52 0.543 3.60E−19 0.643
TWIST2 0.688 4.60E−42 0.551 8.70E−20 0.620
SNAI1 0.514 2.20E−09 0.344 1.70E−09 0.416 4.20E−11 0.425
TWIST1 −0.137 1.40E−01 0.715 1.30E−46 0.670 1.50E−31 0.416
Mesenchymal
VIM 0.656 5.50E−16 0.782 4.00E−61 0.695 8.80E−35 0.711
ACTA2 0.679 2.00E−17 0.656 4.90E−37 0.631 3.40E−27 0.655
FN1 0.415 2.80E−06 0.642 4.90E−35 0.605 1.50E−24 0.554
CDH2 0.373 2.90E−05 0.649 5.20E−36 0.544 2.70E−19 0.522
Epithelial
Plakophilin-2 −0.333 2.10E−04 −0.396 2.50E−12 −0.334 1.80E−07 −0.354
Occludin −0.168 7.00E−02 −0.402 1.10E−12 −0.369 6.80E−09 −0.313
CDH1 −0.324 3.20E−04 −0.394 3.50E−12 −0.200 2.20E−03 −0.306
Villin −0.295 1.10E−03 −0.293 3.70E−07 −0.229 4.30E−04 −0.272
Association of individual genes from KEGG and GO pathways that are significantly associated with PDGFRB expression in all three tumor cohorts. Individual genes were included if they were
significantly associated with PDGFRB in at least two of three data sets. The genes are ordered according to the strength of the correlation across data sets (mean R value; last column).
Figure W3. TGFB pathway genes co-expressed with PDGFRB in CRC. Genes within the TGFB KEGG pathway that are significantly asso-
ciated with PDGFRB expression in a single cohort [3]. Positive correlations with PDGFRB are shown in green, and negative correlations are
shown in red.
Figure W4. PDGF stimulation and PDGFRB knockdown do not affect proliferation of CRC cell lines. (A) C26 andMC38 cells were stimulated
with PDGF-BB (10 ng/ml) for 0 to 5 days and growth curves were generated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
mitochondrial activity assays. The graphs represent two independent experiments performed in triplicate. Data are expressed as fold
change of absorbance values relative to day 0 (=1). Error bars reflect SEM. (B) PDGFRB expression in C26 and MC38 cells was suppressed
by siRNA-mediated knockdown (see Figure W4 for confirmation of knockdown). Control cells received scrambled siRNAs. The resulting
cell populations were then either left unstimulated or were stimulated with PDGF-BB. Growth curves over 0 to 5 days were then generated
as in A.
Figure W5. Suppression of PDGFRB by siRNA transfection in colorectal tumor cells. (A) Western blot showing PDGFRB expression in C26
cells transfected with siRNA against PDGFRB or a control siRNA over time. (B) Western blot showing PDGFRB expression in C26siPDGFRB
expressing firefly luciferase transfected with siRNA against PDGFRB or a control siRNA over time. Cells were injected into the spleens of
Balb/c mice 2 days post-transfection. (C) Sequences of the siRNA SMARTpool targeting PDGFRB and the non-targeting siRNA pool that
was used as a control.
Figure W6. Validation of ALK5 inhibition by SB431524. Western blot
showing SMAD2 phosphorylation following pre-treatment with the
ALK5 inhibitor SB431524 (10 μg/ml; 1 week) and subsequent stimu-
lation with TGFB (10 ng/ml; 45 minutes).
Figure W7. Validation of platelet activation by TRAP or CRP, prevention of activation by iloprost, and repetition of platelet–tumor cell
complex formation in MC38. (A) Flow cytometry analysis of CD42b and P-selectin expression on platelets isolated from donor blood.
Platelets were either left untreated (left panel), were treated with TRAP (middle panel; 30 minutes, 2.5 μM), or were pre-treated with iloprost
(30 minutes; 2 μM) and subsequently treated with TRAP (right panel). Bar graph represents data from two independent experiments.
Error bars represent SEM. (B) MC38 tumor cell–platelet interactions were assessed exactly as in Figure 7A. (C) Flow cytometry analysis
of CD42b and P-selectin expression on platelets isolated from donor blood. Platelets were untreated (middle panel) or treated with CRP
(right panel; 15minutes; 10 μg/ml). The bar graph represents the percentages of CD42b-positive platelets (white bar) and CD42b/P-selectin–
positive platelets (gray bar).
